Supported by

TAVI (Transcatheter aortic valve implantation)

Here you will find all the latest content on transcatheter aortic valve implantations (TAVI) published on this website. Results are listed in chronological order.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Find out more…

Filtered By

571 results

Valvular interventions LIVE demonstration: coronary artery disease in TAVI patients

16 May 2017 – From EuroPCR 2017

Consult this session on coronary artery disease in TAVI patients that include a LIVE demonstration from Saint Thomas' Hospital, London, a 87-year old female patient.

SAVR or TAVI for a patient at high risk for stroke?

Stroke is one of the “devastating” consequences of valve replacement. Join A. P. Kappetein as he reviews what we know today from the first randomised trial to include a complete and detailed neurological exam before intervention. How did TAVI using a self-expanding bioprostheses compare to SAVR in term of treating patients at high-risk for stroke? Learn more here…

REPRISE III - A prospective randomised investigation of a novel TAVI system

From EUROPCR 2017

A pivotal trial which for the first time compares – head-to-head, valve-to-valve – the LOTUS valve with the self-expanding CoreValve. Join T. Feldman and learn whether non-inferiority or primary effectiveness was reached. Find out who was included in this global trial and discover results such as 30-day safety and 1-year effectiveness; hear about the effectiveness of LOTUS in relation to stroke or paravalvular leak; or the high performance of CoreValve when it comes to pacing or haemodynamics. Learn more here…

EuroPCR 2017 Highlights: Interventions for Valvular Diseases

20 May 2017

Spotlight on valvular disease at EuroPCR 2017 with N. Piazza, B. Prendergast and A. Latib. In the aortic space, we look at 4-year results from the NOTION trial on valve durability or the REPRISE trial comparing different devices. The mitral space remains exciting with emerging data on a new device allowing edge-to-edge repair or the use of aortic devices in the mitral valve. The tricuspid? From innovation day through the course itself, there is great promise for the future with 3 trials now ongoing in Europe alone. Get your take-home message here...

Potential pitfalls of TAVI in low-risk patients

19 May 2017 – From EuroPCR 2017

Combined transcatheter valvular procedures: who, how and when? A case-based discussion

18 May 2017 – From EuroPCR 2017

AICT and APSIC@EuroPCR: challenging learning cases of endovascular interventions in Asia-Pacific region

18 May 2017 – From EuroPCR 2017

Treatment dilemmas in TAVI interventions

18 May 2017 – From EuroPCR 2017

The Netherlands and Switzerland share their most educational cases: complications in TAVI

18 May 2017 – From EuroPCR 2017

Moderated posters - session 4

18 May 2017 – From EuroPCR 2017